Novartis
5 abstracts
Abstract
The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).Org: Department of Molecular Oncology & Immunology, Netherlands Cancer Institute (Netherlands), Hartwig Medical Foundation, Erasmus Medical Cancer Institute, Department of Biometrics,
Abstract
New insights on oncologist use of genomic testing.Org: Research Advocacy Network/Komen AIS, Irvina, CA, CBWhite, City of Hope Comprehensive Cancer Center, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center,
Abstract
Examining molecular testing practices and targeted therapy use in advanced/metastatic non-small cell lung cancer (mNSCLC): A quality improvement initiative across ten community cancer centers.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, PRIME Education LLC,
Abstract
Quality care of patients with HR+/HER2- breast cancer: Insights from an implementation science program.Org: PRIME Education LLC, Baylor University Medical Center, Texas Oncology, US Oncology Research,
Abstract
An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects.Org: Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, Tohoku University Hospital, Sendai-Shi Aoba-Ku, MIYAGI-KEN, Japan, Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Hokkaido University Hospital, Sapporo-Shi, Japan,